Literature DB >> 19659749

MHC2TA rs4774C and HHV-6A active replication in multiple sclerosis patients.

R Alvarez-Lafuente1, A Martinez, M Garcia-Montojo, A Mas, V De Las Heras, M I Dominguez-Mozo, C Maria Del Carmen, M López-Cavanillas, M Bartolome, E Gomez de la Concha, E Urcelay, R Arroyo.   

Abstract

BACKGROUND AND
PURPOSE: In a previous report, a strong gene-environment interaction between human herpesvirus 6A (HHV6A) active replication and MHC2TA rs4774C was demonstrated. The objectives of this study were: (i) to reappraise the association that was found in the previous study; (ii) to evaluate if MS patients with minor allele C and HHV-6A active infection had different clinical behavior; and (iii) to analyze the possible association of MHC2TA rs4774C with Epstein-Barr virus (EBV).
METHODS: A total of 149 MS patients were analyzed both at the MHC2TA locus and by HHV-6A status in serum. We studied a G/C polymorphism (rs4774) by a TaqMan Assay-on-Demand. HHV-6A genomes in serum were evaluated by quantitative PCR. A control group of 562 healthy Spanish individuals was included for comparative purposes in the genetic analyses. A battery of clinical data was collected for all the MS patients included in the study.
RESULTS: (i) MHC2TA/HHV-6A interaction: we found the same strong association of the rs4774C allele with HHV-6A active replication than in the previous study (P = 0.0001). (ii) CLINICAL DATA: the two main statistical significant differences for MS patients with HHV-6A active infection and minor allele C were: (a) a significant number of them were not free of progression (EDSS = 0) 2 years after the diagnosis (P = 0.01); (b) only a third of them responded to interferon beta treatment (P = 0.05).
CONCLUSIONS: This study has verified previous results about the strong gene-environment interaction between HHV6A active replication and MHC2TA rs4774C. Furthermore, a different clinical behavior for MS patients with HHV-6A active infection and minor allele C was found.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19659749     DOI: 10.1111/j.1468-1331.2009.02758.x

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  14 in total

Review 1.  Pharmacogenomics and multiple sclerosis: moving toward individualized medicine.

Authors:  Manuel Comabella; Koen Vandenbroeck
Journal:  Curr Neurol Neurosci Rep       Date:  2011-10       Impact factor: 5.081

2.  CIITA variation in the presence of HLA-DRB1*1501 increases risk for multiple sclerosis.

Authors:  Paola G Bronson; Stacy Caillier; Patricia P Ramsay; Jacob L McCauley; Rebecca L Zuvich; Philip L De Jager; John D Rioux; Adrian J Ivinson; Alastair Compston; David A Hafler; Stephen J Sawcer; Margaret A Pericak-Vance; Jonathan L Haines; Stephen L Hauser; Jorge R Oksenberg; Lisa F Barcellos
Journal:  Hum Mol Genet       Date:  2010-03-08       Impact factor: 6.150

Review 3.  Chemokines encoded by herpesviruses.

Authors:  Sergio M Pontejo; Philip M Murphy
Journal:  J Leukoc Biol       Date:  2017-08-28       Impact factor: 4.962

Review 4.  Classification of HHV-6A and HHV-6B as distinct viruses.

Authors:  Dharam Ablashi; Henri Agut; Roberto Alvarez-Lafuente; Duncan A Clark; Stephen Dewhurst; Dario DiLuca; Louis Flamand; Niza Frenkel; Robert Gallo; Ursula A Gompels; Per Höllsberg; Steven Jacobson; Mario Luppi; Paolo Lusso; Mauro Malnati; Peter Medveczky; Yasuko Mori; Philip E Pellett; Joshua C Pritchett; Koichi Yamanishi; Tetsushi Yoshikawa
Journal:  Arch Virol       Date:  2013-11-06       Impact factor: 2.574

5.  Modulation of microRNome by Human Cytomegalovirus and Human Herpesvirus 6 Infection in Human Dermal Fibroblasts: Possible Significance in the Induction of Fibrosis in Systemic Sclerosis.

Authors:  Irene Soffritti; Maria D'Accolti; Gloria Ravegnini; Maria-Cristina Arcangeletti; Clara Maccari; Flora De Conto; Adriana Calderaro; Elisabetta Caselli
Journal:  Cells       Date:  2021-04-29       Impact factor: 6.600

6.  Virologic and immunologic evidence supporting an association between HHV-6 and Hashimoto's thyroiditis.

Authors:  Elisabetta Caselli; Maria Chiara Zatelli; Roberta Rizzo; Sabrina Benedetti; Debora Martorelli; Giorgio Trasforini; Enzo Cassai; Ettore C degli Uberti; Dario Di Luca; Riccardo Dolcetti
Journal:  PLoS Pathog       Date:  2012-10-04       Impact factor: 6.823

7.  Anti-human herpesvirus 6A/B IgG correlates with relapses and progression in multiple sclerosis.

Authors:  Isabel Ortega-Madueño; Marta Garcia-Montojo; Maria Inmaculada Dominguez-Mozo; Angel Garcia-Martinez; Ana Maria Arias-Leal; Ignacio Casanova; Rafael Arroyo; Roberto Alvarez-Lafuente
Journal:  PLoS One       Date:  2014-08-11       Impact factor: 3.240

Review 8.  Multiple sclerosis: an example of pathogenic viral interaction?

Authors:  Walter Fierz
Journal:  Virol J       Date:  2017-02-28       Impact factor: 4.099

9.  MHC2TA mRNA levels and human herpesvirus 6 in multiple sclerosis patients treated with interferon beta along two-year follow-up.

Authors:  Maria Inmaculada Dominguez-Mozo; Marta Garcia-Montojo; Virginia De Las Heras; Angel Garcia-Martinez; Ana Maria Arias-Leal; Ignacio Casanova; Rafael Arroyo; Roberto Alvarez-Lafuente
Journal:  BMC Neurol       Date:  2012-09-25       Impact factor: 2.474

10.  Coinfection of human herpesviruses 6A (HHV-6A) and HHV-6B as demonstrated by novel digital droplet PCR assay.

Authors:  Emily C Leibovitch; Giovanna S Brunetto; Breanna Caruso; Kaylan Fenton; Joan Ohayon; Daniel S Reich; Steven Jacobson
Journal:  PLoS One       Date:  2014-03-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.